• Human Genome Exhibition Set to Mark Project’s 10th Anniversary

    Bio-IT World | The Smithsonian Institution in Washington, D.C., is planning a “high-tech, high-intensity” museum exhibition next year to mark the 10th anniversary of the official completion of the Human Genome Project, with millions of dollars pledged already by the Life Technologies Foundation, the Brin Wojcicki Foundation, and other donors.   

    May 21, 2012

  • California Considers New Genetic Privacy Law

    Scientific American | First there was GINA, now GIPA? The Genetic Information Privacy Act, currently under consideration by California lawmakers, would require an individual's written consent for the collection, analysis, or sharing of any genetic information. 

    May 21, 2012

  • Accelrys Buys Cloud Discovery Platform

    Zacks | Accelrys has bought a Cloud-based drug discovery and development platform from SCYNEXIS, completing the contract both companies entered into last year. 

    May 20, 2012

  • Rare Mutations Mean Less Disease Correlation

    Bloomberg | In a paper released last week in Science, researchers at the University of Washington show that most genetic variations in people are rare and evolutionarily recent. The findings further reinforce the changes being made to how we think about correlating genetic changes with diseases. 

    May 20, 2012

  • Human Genome Sciences Seeks to Fend Off GSK

    New York Times | Human Genome Sciences is still rejecting a bid from GlaxoSmithKline to buy the biotech. Human Genome Sciences' board voted unanimously to reject the GSK offer and adopt a shareholders' rights plan, or poison pill. 

    May 17, 2012

  • Driving Innovation from Within

    2012 Bio-IT World Best Practices Winner | “It’s survival of the fittest,” explains Ulrich Betz, department head of Merck Serono’s Innovation & Entrepreneurship Incubator, of Merck’s innospire program, winner of the 2012 Bio-IT World Best Practices award for Knowledge Management. Only the best ideas win. 

    May 17, 2012

  • Pfizer's Lung Cancer Drug Targets ALK Gene

    Wall Street Journal | Pfizer's new lung cancer drug is showing effectiveness against childhood cancers with defects in the ALK gene. 

    May 16, 2012

  • BGI Installs Roche System for Long Reads

    Bio-IT World | BGI has garnered a lot of attention for its sheer sequencing capacity. Now the sequencing center has installed a new Roche GS FLX+ System at its Shenzhen facility to enhance BGI's long read sequencing capabilities and supplement the short read technologies.

    May 16, 2012

  • GSK Buys Proteomics Company

    Fox Business | GlaxoSmithKline has purchased the remaining percentage of Cellzome for about $98 million in cash. 

    May 16, 2012

  • The Goals of the National Center for Advancing Translational Sciences

    Forbes | Last year NIH set up the National Center for Advancing Translational Sciences to overcome bottlenecks and accelerate the development of diagnostics and therapeutics. Recently, the Center's mandate has been further expanded. 

    May 16, 2012

  • 454, SoftGenetics Enter Promotion Agreement

    Bio-IT World | 454 Life Sciences and SoftGenetics have entered into a co-promotion agreement designed to provide users of 454 Sequencing Systems the broad range of next-generation sequencing data analysis options provided by SoftGenetics NextGENe software.

    May 15, 2012

  • Pitfalls Aplenty for Observational Research

    Bio-IT World | Limitations on the use of observational data in comparative effectiveness research (CER) were among the themes of a Post-Approval Summit held in early May at Harvard Medical School*. The march toward bigger and often mandatory post-approval studies needs to be rooted in “strong science,” enabled by industry partnerships with large health care delivery organizations, insurers, the Food and Drug Administration (FDA), and academia, according to keynote speaker Michael Rosenblatt, executive vice president and chief medical officer at Merck. 

    May 13, 2012

  • Best Practices: Bringing the Trial to the Patient

    2012 Bio-IT World Best Practices Winner | Almost a year ago, Pfizer started recruiting for a different kind of clinical trial: the first ever conducted under a Participatory Patient-Centered (PPC) model. Last month, the team’s efforts—still very much ongoing—were rewarded with a Bio-IT World Best Practices Award in the Clinical and Health IT category. 

    May 10, 2012

  • Drug Timing Affects Efficacy

    MIT News | Researchers at MIT and Dana Farber have shown that staggering cancer drugs produces better results--in very specific ways. The results were published in Cell today. 

    May 10, 2012

  • More Thoughts on Sequence Analysis

    Xconomy | We are generally agreed that the analysis side of the next generation sequencing coin is becoming the toughest. Even if you get your sequence in a day, then you have to process it.

    May 9, 2012

  • GSK Launches Hostile Takeover Bid for Human Genome Sciences

    Baltimore Sun | GlaxoSmithKline has launched a hostile takeover bid for long-time partner Human Genome Sciences worth $2.6 billion, or $13/share. 

    May 9, 2012

  • Manolis Kellis, Epigenetics, and the Future of Fighting Disease

    Bio-IT World | BOSTON—Manolis Kellis, professor of computer science at MIT, addressed the Bio-IT World Conference on efforts to revolutionize the study of human disease by bridging the gap between genetics and epigenetics. 

    May 9, 2012

  • Introducing the Bina Box

    Technology Review | Bina Technologies is throwing its hat into the genome analysis ring with an in-house analyzer that can upload the resulting genetic profiles to the company's cloud-hosted site for data management, sharing, and aggregation. 

    May 8, 2012

  • Editors' Asian Favorites

    Bio-IT World | Bio-IT World has invited a group of superb world-renowned speakers from across Asia, Europe, and North America for its very first conference in Asia (Marina Bay Sands, Singapore; June 6-8, 2012). They will present the latest advances in research and technology in areas such as next-gen sequencing, personalized medicine, high-performance and cloud computing, bioinformatics, drug discovery and development, and translational research. Read on for some of the editor's favorites. 

    May 7, 2012

  • The Merits of Data Sharing in Tackling Rare Diseases

    Bio-IT World | BOSTON—Alex Sherman, director of systems in neurology at Massachusetts General Hospital (MGH) presented promising new initiatives in the battle against rare diseases at the Bio-IT World Conference. Sherman proposed a model for dealing with the many obstacles that confront research on rare diseases. 

    May 7, 2012